HLS Therapeutics (FRA:74D) Cyclically Adjusted FCF per Share: €0.51 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:74D HLS Therapeutics Inc FRA:74D
68 GF Score
Price €2.22
GF Value €2.50
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics Cyclically Adjusted FCF per Share?

HLS Therapeutics FRA:74D -0.89% 68 Cyclically Adjusted FCF per Share is €0.51 as of Jun. 2026. GuruFocus rates FRA:74D with a GF Score™ of 68/100 and a GF Value™ of €2.50. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

HLS Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was €0.079. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.51 for the trailing ten years ended in Jun. 2026.

During the past 12 months, HLS Therapeutics's average Cyclically Adjusted FCF Growth Rate was 14.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -2.00% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 2.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of HLS Therapeutics was 111.80% per year. The lowest was -9.20% per year. And the median was 16.25% per year.

As of today (2026-08-20), HLS Therapeutics's current stock price is €2.22. HLS Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €0.51. HLS Therapeutics's Cyclically Adjusted Price-to-FCF of today is 4.35.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of HLS Therapeutics was 24.01. The lowest was 2.89. And the median was 8.00.


HLS Therapeutics  (FRA:74D) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

HLS Therapeutics's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=2.22/0.51
=4.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of HLS Therapeutics was 24.01. The lowest was 2.89. And the median was 8.00.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


HLS Therapeutics Cyclically Adjusted FCF per Share Related Terms


HLS Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for HLS Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HLS Therapeutics Cyclically Adjusted FCF per Share Chart

HLS Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.58 0.57 0.53 0.49 0.49

HLS Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.47 0.49 0.53 0.51

FRA:74D vs ZTS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


FRA:74D
68GF Score
HLS Therapeutics Inc FRA:74D
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HLS Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, HLS Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.079/133.5265*133.5265
=0.079

Current CPI (Jun. 2026) = 133.5265.

HLS Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.070 101.765 0.092
201612 1.581 101.449 2.081
201703 -0.034 102.634 -0.044
201706 -0.045 103.029 -0.058
201709 -0.002 103.345 -0.003
201712 0.872 103.345 1.127
201803 0.425 105.004 0.540
201806 0.465 105.557 0.588
201809 0.197 105.636 0.249
201812 0.347 105.399 0.440
201903 0.260 106.979 0.325
201906 0.262 107.690 0.325
201909 -0.079 107.611 -0.098
201912 -0.080 107.769 -0.099
202003 -0.043 107.927 -0.053
202006 -0.178 108.401 -0.219
202009 -0.811 108.164 -1.001
202012 0.078 108.559 0.096
202103 0.154 110.298 0.186
202106 -0.021 111.720 -0.025
202109 0.088 112.905 0.104
202112 0.097 113.774 0.114
202203 0.160 117.646 0.182
202206 0.100 120.806 0.111
202209 -0.183 120.648 -0.203
202212 0.102 120.964 0.113
202303 0.116 122.702 0.126
202306 0.076 124.203 0.082
202309 0.156 125.230 0.166
202312 0.107 125.072 0.114
202403 0.022 126.258 0.023
202406 0.074 127.522 0.077
202409 0.043 127.285 0.045
202412 0.096 127.364 0.101
202503 0.102 129.181 0.105
202506 0.096 129.892 0.099
202509 0.060 130.287 0.061
202512 0.169 130.366 0.173
202603 0.166 132.262 0.168
202606 0.079 133.527 0.079

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €0.51 mean?
HLS Therapeutics (FRA:74D) has a Cyclically Adjusted FCF per Share of €0.51 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on HLS Therapeutics and its competitors.
Is HLS Therapeutics' Cyclically Adjusted FCF per Share too high?
HLS Therapeutics' current Cyclically Adjusted FCF per Share is €0.51. Overall, HLS Therapeutics has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Cyclically Adjusted FCF per Share compare to ZTS?
HLS Therapeutics' Cyclically Adjusted FCF per Share of €0.51 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on HLS Therapeutics and its competitors. HLS Therapeutics's current Cyclically Adjusted FCF per Share is €0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
HLS Therapeutics (FRA:74D) has a current Cyclically Adjusted FCF per Share of €0.51. The stock's GF Value™ is €2.50, compared to a current price of €2.22 — trading 11.2% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €0.51. HLS Therapeutics' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For HLS Therapeutics (FRA:74D), the current Cyclically Adjusted FCF per Share is €0.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HLS Therapeutics (FRA:74D) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of €2.22 is trading 11.2% below its estimated GF Value™ of €2.50.

Key valuation signals for FRA:74D:

  • Cyclically Adjusted FCF per Share: €0.51
  • GF Value™: €2.50 vs. price of €2.22 (11.2% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the FRA:74D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HLS Therapeutics Business Description

Other Exchanges HLTRF:USAHLS:Canada
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
68GF Score

Get the complete analysis for FRA:74D

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.22
Price
€2.50
GF Value